H.Res. 309 · 118th Congress
Expressing the sense of the House of Representatives that the Food and Drug Administration has the authority…
Full title
Expressing the sense of the House of Representatives that the Food and Drug Administration has the authority to approve drugs for abortion care.
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 118th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
ManningSponsor48 cosponsors · 48 D
D
Auchincloss
NN
D
(Nikki) Budzinski
GC
D
Connolly
JC
D
Chu
JC
D
Crockett
GC
D
Casar
YC
D
Caraveo
CD
D
Deluzio
VE
D
Escobar
BH
D
Higgins
GI
D
Ivey
RL
D
Larsen
GL
D
Landsman
GM
D
Moore
GM
D
Meng
FM
D
Mrvan
EN
D
Norton
WN
D
Nickel
JP
D
Panetta
CP
D
Pappas
AP
D
Pressley
KP
D
Porter
BP
D
Pettersen
JS
D
Schakowsky
BS
D
Schneider
MS
D
Scanlon
ES
D
Sykes
AS
D
Salinas
DT
D
Titus
PT
D
Tonko
JT
D
Tokuda
NW
D
Williams
SW
D
Wild
CB
D
Bush
JB
D
Brownley
SD
D
Davids
JG
D
Gottheimer
SK
D
Kamlager-Dove
ML
D
Levin
BM
D
McCollum
HS
D
Stevens
DW
D
Wasserman Schultz
BB
D
Balint
DR
D
Ross
JR
D
Raskin
TC
D
Carter
RK
D
Kelly
MS
D
Sherrill33 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This resolution expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) has the authority to review and approve drugs pursuant to its own expertise, and that recent court decisions blocking the FDA's approval of mifepristone (which is used in medication abortion) violate congressional intent with respect to the FDA's…
What it does: CRS summary · Introduced in House · Apr 19, 2023
This resolution expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) has the authority to review and approve drugs pursuant to its own expertise, and that recent court decisions blocking the FDA's approval of mifepristone (which is used in medication abortion) violate congressional intent with respect to the FDA's authority.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Expressing the sense of the House of Representatives that the Food and Drug Administration has the authority to approve drugs for abortion care.
Latest action (Apr 19, 2023): Referred to the House Committee on Energy and Commerce.
Policy area: Health · Origin: House · Introduced: Apr 19, 2023
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.